KIT and mastocytosis: Mutations in the tumor suppressor gene TET2 act in synergy with KIT D816V mutation, enhance its oncogenic potency, and induce aggressiveness of the mastocytosis (25), but in contrast to other mutations have not been associated with decreased overall survival (26–28).